Published 17:12 IST, January 23rd 2024
France's Sanofi boosts rare disease business with about $2.2 bln Inhibrx deal
Inhibrx shareholders are set to receive $30 per share in cash, along with one contingent value right valued at $5.
France's Sanofi boosts rare disease business with about $2.2 bln Inhibrx deal | Image:
Shutterstock
- Listen to this article
- 2 min read
Advertisement
17:12 IST, January 23rd 2024